Once-Weekly Hemophilia Preventive Injection: Pfizer Expands HYMPAVZI’s U.S. Indication

For people with hemophilia, treatment is not only about stopping a single bleed, but about reducing bleeding risk enough to make daily life a little less interrupted. The U.S. Food and Drug Administration recently expanded approval of Pfizer’s HYMPAVZI, allowing this once-weekly subcutaneous preventive therapy to be used in a broader population of patients with hemophilia A and B.

Pfizer said the label expansion covers patients aged 12 and older with hemophilia A or B who have clotting factor inhibitors, as well as pediatric patients aged 6 to 11, regardless of whether they have inhibitors. The latest prescribing information describes the indication as routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 6 years and older with hemophilia A or B, with or without clotting factor inhibitors.

Hemophilia A and B are associated with deficiencies in clotting factors VIII and IX, respectively. In some patients, after receiving clotting factor therapy, the immune system produces “inhibitors,” making the supplemented clotting factor less effective and clinical care more difficult. HYMPAVZI’s active ingredient, marstacimab, does not replace the missing clotting factor. Instead, by inhibiting tissue factor pathway inhibitor, it attempts to shift the coagulation balance back toward a state less prone to bleeding.

This approval is mainly supported by two Phase 3 studies. Pfizer’s press release stated that in the inhibitor population of the BASIS study, HYMPAVZI reduced mean treated annualized bleeding rate by 93% compared with on-demand bypassing agents. ClinicalTrials.gov registration records provide background on the designs, participant criteria, endpoints, and trial status of the BASIS and BASIS KIDS studies, serving as the clinical trial framework for understanding the basis of approval.

Pediatric dosing is also clearer in the updated prescribing information. For children aged 6 to under 12, the label lists a 150 mg starting dose, followed by 75 mg administered subcutaneously once weekly. This shifts the treatment pathway from a care model that previously relied more heavily on frequent intravenous infusions toward a lower-frequency, subcutaneous preventive regimen; for families and pediatric care, that convenience may have practical significance.

However, expanded use does not mean risks disappear. The prescribing information updated the indication, dosage and administration, and warnings and precautions in June 2026, and records that thromboembolic events occurred in patients treated with HYMPAVZI in an open-label extension study, at a rate of 0.8%. For a drug that works by adjusting the coagulation balance, this type of safety signal is something physicians cannot overlook when assessing a patient’s medical history, concomitant medications, and monitoring strategy.

Therefore, the significance of this approval is not that it declares hemophilia treatment has been simplified into a single answer, but that it adds another option to the preventive treatment toolbox, one that can span type A, type B, and inhibitor status. Its real clinical value will still take shape gradually across patients of different ages, bleeding patterns, and treatment burdens, through long-term follow-up and real-world use experience.